MedPath

南京圣和药业股份有限公司

Ownership
-
Established
1996-09-19
Employees
-
Market Cap
-
Website
www.sanhome.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

86

NMPA:86

Drug Approvals

Rilertinib Mesylate Tablets

Product Name
圣瑞沙
Approval Number
国药准字H20240020
Approval Date
Jun 11, 2024
NMPA

Alfosbuvir Tablets

Product Name
圣诺迪
Approval Number
国药准字H20230010
Approval Date
May 12, 2023
NMPA

Daclatasvir Hydrochloride Tablets

Product Name
盐酸达拉他韦片
Approval Number
国药准字H20223191
Approval Date
Mar 29, 2022
NMPA

Ornidazole Injection

Product Name
奥硝唑注射液
Approval Number
国药准字H20227004
Approval Date
Jan 18, 2022
NMPA

藏茄流浸膏

Approval Number
国药准字Z41020568
Approval Date
Sep 9, 2021
NMPA

Azithromycin for Injection

Product Name
注射用阿奇霉素
Approval Number
国药准字H20213559
Approval Date
Jun 29, 2021
NMPA

Finasteride

Product Name
非那雄胺
Approval Number
国药准字H20041664
Approval Date
Mar 5, 2021
NMPA

柴胡注射液

Approval Number
国药准字Z41020051
Approval Date
Mar 5, 2021
NMPA

Loratadine

Product Name
氯雷他定
Approval Number
国药准字H20041657
Approval Date
Mar 5, 2021
NMPA

Aniracetam

Product Name
茴拉西坦
Approval Number
国药准字H20053687
Approval Date
Mar 5, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.